AIMS: Cholesterol efflux with high-density lipoprotein (HDL) particles has an important role in the first step of reverse cholesterol transport (RCT). However, HDL function in type 2 diabetes has not been well investigated thoroughly. We measured cholesterol efflux in 36 patients with type 2 diabetes compared with 9 controls without diabetes. METHODS: The HDL fraction was separated with polyacrylamide gel and recovered using the protein recovery system. Concentration adjusted HDL fraction was used to determine HDL-mediated cholesterol efflux (Efflux-hdl) from THP-1 derived macrophages. We measured paraoxonase-1 (PON 1) activity to determine antioxidation capacity, serum amyloid A protein (SAA) to determine inflammatory response, and carboxymethyl-lysin (CML) to determine antiglucoxidative capacity. RESULTS: Efflux-hdl demonstrated no correlation with plasma apoprotein A-1 (ApoA-I) or HDL-cholesterol in patients with diabetes. PON1 activity in the patients' HDL fraction was positively correlated with Efflux-hdl (r=0.39, p=0.02), and showed a negative tendency with HbA1c levels (r=-0.28, p=0.10). SAA and CML levels did not demonstrate correlation with Efflux-hdl in patients with diabetes. CONCLUSION: We confirmed the functional changes in HDL particles in the patients. Efflux-hdl from macrophages was reduced depending upon the decrease in PON1 activity, which was inversely related to HbA1c levels.
AIMS: Cholesterol efflux with high-density lipoprotein (HDL) particles has an important role in the first step of reverse cholesterol transport (RCT). However, HDL function in type 2 diabetes has not been well investigated thoroughly. We measured cholesterol efflux in 36 patients with type 2 diabetes compared with 9 controls without diabetes. METHODS: The HDL fraction was separated with polyacrylamide gel and recovered using the protein recovery system. Concentration adjusted HDL fraction was used to determine HDL-mediated cholesterol efflux (Efflux-hdl) from THP-1 derived macrophages. We measured paraoxonase-1 (PON 1) activity to determine antioxidation capacity, serum amyloid A protein (SAA) to determine inflammatory response, and carboxymethyl-lysin (CML) to determine antiglucoxidative capacity. RESULTS: Efflux-hdl demonstrated no correlation with plasma apoprotein A-1 (ApoA-I) or HDL-cholesterol in patients with diabetes. PON1 activity in the patients' HDL fraction was positively correlated with Efflux-hdl (r=0.39, p=0.02), and showed a negative tendency with HbA1c levels (r=-0.28, p=0.10). SAA and CML levels did not demonstrate correlation with Efflux-hdl in patients with diabetes. CONCLUSION: We confirmed the functional changes in HDL particles in the patients. Efflux-hdl from macrophages was reduced depending upon the decrease in PON1 activity, which was inversely related to HbA1c levels.
Authors: Carlo Cervellati; Giuseppe Valacchi; Veronica Tisato; Giovanni Zuliani; Judit Marsillach Journal: Minerva Med Date: 2018-10-11 Impact factor: 4.806
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Marleen M J van Greevenbroek; Carla J H van der Kallen; Casper G Schalkwijk; Coen D A Stehouwer; Robin P F Dullaart; Uwe J F Tietge Journal: Sci Rep Date: 2016-06-08 Impact factor: 4.379
Authors: Kayleigh Griffiths; Agnieszka Pazderska; Mohammed Ahmed; Anne McGowan; Alexander P Maxwell; Jane McEneny; James Gibney; Gareth J McKay Journal: J Diabetes Res Date: 2017-05-09 Impact factor: 4.011
Authors: S Contreras-Duarte; P Chen; M Andía; S Uribe; P Irarrázaval; S Kopp; S Kern; G Marsche; D Busso; C Wadsack; A Rigotti Journal: Biol Res Date: 2018-09-15 Impact factor: 5.612
Authors: Sanam Ebtehaj; Eke G Gruppen; Mojtaba Parvizi; Uwe J F Tietge; Robin P F Dullaart Journal: Cardiovasc Diabetol Date: 2017-10-12 Impact factor: 9.951